- Home
- Na Circulating Tumor Cells Ctc Liquid Biopsy Market
NA Circulating Tumor Cells (CTC) Liquid Biopsy Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-198 | No of pages: 134 | Format:
North America circulating tumor cells (CTC) liquid biopsy market is projected to register a substantial CAGR of 16.0% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020, and the forecast period is 2021 to 2028.
Market Segmentation:
North America Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (U.S., Canada, Mexico) - Industry Trends and Forecast -2029
Some of the major factors contributing to the growth of the North America circulating tumor cells (CTC) liquid biopsy market are:
Presence of big players in the market
Increasing R&D
Technological advancement
Market Players:
The major companies which are dealing in the North America circulating tumor cells (CTC) liquid biopsy market are listed below:
Eurofins Genomics ( a subsidiary of Eurofins Scientific)
MDx Health
Guardant Health
IMMUCOR
Thermo Fisher Scientific, Inc.
Menarini Silicon Biosystems
QIAGEN
Exact Sciences Corporation
Myriad Genetics, Inc.
LungLife AI, Inc.
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Natera Inc.
ExoDx ( a subsidiary of Bio-Techne Corporation)
Biocept, Inc.
F. Hoffman-La Roche Ltd.
FOUNDATION MEDICINE, INC.
Lucence Health, Inc.
Inivata Ltd
Biolidics Limited
Vortex Biosciences
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 20
1.4 LIMITATIONS 21
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 DBMR TRIPOD DATA VALIDATION MODEL 27
2.6 MULTIVARIATE MODELLING 30
2.7 TECHNOLOGY LIFELINE CURVE 30
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.9 DBMR MARKET POSITION GRID 32
2.10 MARKET APPLICATION COVERAGE GRID 33
2.11 VENDOR SHARE ANALYSIS 34
2.12 SECONDARY SOURCES 35
2.13 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 38
4.1 PESTEL ANALYSIS 39
4.2 PORTERS FIVE FORCES 40
5 REGULATIONS: NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 42
5.1 ROLE OF FDA 42
5.2 ROLE OF CDC AND HCFA 42
6 MARKET OVERVIEW 44
6.1 DRIVERS 46
6.1.1 HIGH PREVALENCE OF CANCER 46
6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY 47
6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER 48
6.1.4 RISE IN FDA APPROVAL 48
6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY 49
6.2 RESTRAINTS 49
6.2.1 DOWNSIDES OF LIQUID BIOPSY 49
6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING 49
6.3 OPPORTUNITIES 50
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 50
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 50
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 51
6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES 52
6.4 CHALLENGES 52
6.4.1 SHORTAGE OF SKILLED PERSONNEL 52
6.4.2 LACK OF ACCESSIBILITY 53
7 COVID-19 IMPACT ON NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 54
7.1 IMPACT ON PRICE 54
7.2 IMPACT ON DEMAND 54
7.3 IMPACT ON SUPPLY 54
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19 55
7.5 CONCLUSION: 55
8 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY 56
8.1 OVERVIEW 57
8.2 CTC DETECTION METHODS 60
8.3 CTC ENRICHMENT METHODS 60
8.4 EX VIVO POSITIVE SELECTION 61
8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES 61
8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY 62
8.7 XENOTRANSPLANTATION MODELS 63
8.8 MICROCHIPS 63
8.9 SINGLE SPIRAL MICROCHANNEL 64
8.10 NEGATIVE SELECTION 65
8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES 66
9 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION 67
9.1 OVERVIEW 68
9.2 CANCER STEM CELL RESEARCH 71
9.3 MULTIPLE CHROMOSOME ABNORMALITIES 71
9.4 OTHERS 72
10 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER 73
10.1 OVERVIEW 74
10.2 RESEARCH & ACADEMIC INSTITUTES 77
10.3 REFERENCE LABORATORIES 77
10.4 HOSPITALS AND PHYSICIAN LABORATORIES 78
11 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION 79
11.1 NORTH AMERICA 80
11.1.1 U.S. 86
11.1.2 CANADA 88
11.1.3 MEXICO 90
12 NORTH AMERICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE 92
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 92
13 SWOT ANALYSIS 93
14 COMPANY PROFILE 94
14.1 GUARDANT HEALTH 94
14.1.1 COMPANY SNAPSHOT 94
14.1.2 REVENUE ANALYSIS 94
14.1.3 COMPANY SHARE ANALYSIS 95
14.1.4 PRODUCT PORTFOLIO 95
14.1.5 RECENT DEVELOPMENTS 95
14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC) 97
14.2.1 COMPANY SNAPSHOT 97
14.2.2 REVENUE ANALYSIS 97
14.2.3 COMPANY SHARE ANALYSIS 98
14.2.4 PRODUCT PORTFOLIO 98
14.2.5 RECENT DEVELOPMENTS 98
14.3 FOUNDATION MEDICINE, INC. 99
14.3.1 COMPANY SNAPSHOT 99
14.3.2 COMPANY SHARE ANALYSIS 99
14.3.3 PRODUCT PORTFOLIO 100
14.3.4 RECENT DEVELOPMENTS 100
14.4 ILLUMINA, INC. 101
14.4.1 COMPANY SNAPSHOT 101
14.4.2 REVENUE ANALYSIS 101
14.4.3 COMPANY SHARE ANALYSIS 102
14.4.4 PRODUCT PORTFOLIO 102
14.4.5 RECENT DEVELOPMENT 102
14.5 NATERA, INC. 103
14.5.1 COMPANY SNAPSHOT 103
14.5.2 REVENUE ANALYSIS 103
14.5.3 COMPANY SHARE ANALYSIS 104
14.5.4 PRODUCT PORTFOLIO 104
14.5.5 RECENT DEVELOPMENT 104
14.6 BIO-RAD LABORATORIES, INC. 105
14.6.1 COMPANY SNAPSHOT 105
14.6.2 REVENUE ANALYSIS 105
14.6.3 PRODUCT PORTFOLIO 106
14.6.4 RECENT DEVELOPMENT 106
14.7 QIAGEN 107
14.7.1 COMPANY SNAPSHOT 107
14.7.2 REVENUE ANALYSIS 107
14.7.3 PRODUCT PORTFOLIO 108
14.7.4 RECENT DEVELOPMENTS 108
14.8 THERMO FISHER SCIENTIFIC INC. 109
14.8.1 COMPANY SNAPSHOT 109
14.8.2 REVENUE ANALYSIS 109
14.8.3 PRODUCT PORTFOLIO 110
14.8.4 RECENT DEVELOPMENTS 110
14.9 BIOCEPT, INC. 111
14.9.1 COMPANY SNAPSHOT 111
14.9.2 REVENUE ANALYSIS 111
14.9.3 PRODUCT PORTFOLIO 112
14.9.4 RECENT DEVELOPMENT 112
14.10 BIOLIDICS LIMITED 113
14.10.1 COMPANY SNAPSHOT 113
14.10.2 REVENUE ANALYSIS 113
14.10.3 PRODUCT PORTFOLIO 114
14.10.4 RECENT DEVELOPMENTS 114
14.11 EXACT SCIENCES CORPORATION 115
14.11.1 COMPANY SNAPSHOT 115
14.11.2 REVENUE ANALYSIS 115
14.11.3 PRODUCT PORTFOLIO 116
14.11.4 RECENT DEVELOPMENT 116
14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION) 117
14.12.1 COMPANY SNAPSHOT 117
14.12.2 REVENUE ANALYSIS 117
14.12.3 PRODUCT PORTFOLIO 118
14.12.4 RECENT DEVELOPMENTS 118
14.13 F. HOFFMANN-LA ROCHE LTD 119
14.13.1 COMPANY SNAPSHOT 119
14.13.2 RECENT FINANCIALS 119
14.13.3 PRODUCT PORTFOLIO 120
14.13.4 RECENT DEVELOPMENTS 120
14.14 IMMUCOR 121
14.14.1 COMPANY SNAPSHOT 121
14.14.2 PRODUCT PORTFOLIO 121
14.14.3 RECENT DEVELOPMENTS 121
14.15 INIVATA LTD 122
14.15.1 COMPANY SNAPSHOT 122
14.15.2 PRODUCT PORTFOLIO 122
14.15.3 RECENT DEVELOPMENTS 122
14.16 LUCENCE HEALTH, INC. 123
14.16.1 COMPANY SNAPSHOT 123
14.16.2 PRODUCT PORTFOLIO 123
14.16.3 RECENT DEVELOPMENTS 123
14.17 LUNGLIFE AI, INC. 124
14.17.1 COMPANY SNAPSHOT 124
14.17.2 PRODUCT PORTFOLIO 124
14.17.3 RECENT DEVELOPMENTS 124
14.18 MDXHEALTH 125
14.18.1 COMPANY SNAPSHOT 125
14.18.2 REVENUE ANALYSIS 125
14.18.3 PRODUCT PORTFOLIO 126
14.18.4 RECENT DEVELOPMENT 126
14.19 MENARINI SILICON BIOSYSTEMS 127
14.19.1 COMPANY SNAPSHOT 127
14.19.2 PRODUCT PORTFOLIO 127
14.19.3 RECENT DEVELOPMENTS 127
14.20 MYRIAD GENETICS, INC. 128
14.20.1 COMPANY SNAPSHOT 128
14.20.2 REVENUE ANALYSIS 128
14.20.3 PRODUCT PORTFOLIO 129
14.20.4 RECENT DEVELOPMENTS 129
14.21 VORTEX BIOSCIENCES 130
14.21.1 COMPANY SNAPSHOT 130
14.21.2 PRODUCT PORTFOLIO 130
14.21.3 RECENT DEVELOPMENTS 130
15 QUESTIONNAIRE 131
16 RELATED REPORTS 134
Segmentation
Short Description
North America Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (U.S., Canada, Mexico) - Industry Trends and Forecast -2029
Market Definition:
The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites. It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.
The circulating tumor cells are a rare sub-set of cells which function as a seed of metastases. It is found in blood of patients who have developed solid tumors. The testing of circulating tumor cells allows the detection and quantification of tumor cells in the blood of cancer patients. The various types of biological phenotypes of circulating tumor cells (CTCs) exits includes stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity. Due to which, their detection needs a phase of isolation-enrichment. After that, a second phase of detection.
Market Segmentation:
North America circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user.
On the basis of technology, circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies
On the basis of application, circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others
On the basis of end user, circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories
Market Players
The major companies which are dealing in the circulating tumor cells (CTC) liquid biopsy market are listed below:
Eurofins Genomics ( a subsidiary of Eurofins Scientific)
MDx Health
Guardant Health
IMMUCOR
Thermo Fisher Scientific, Inc.
Menarini Silicon Biosystems
QIAGEN
Exact Sciences Corporation
Myriad Genetics, Inc.
LungLife AI, Inc.
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Natera Inc.
ExoDx ( a subsidiary of Bio-Techne Corporation)
Biocept, Inc.
F. Hoffman-La Roche Ltd.
FOUNDATION MEDICINE, INC.
Lucence Health, Inc.
Inivata Ltd
Biolidics Limited
Vortex Biosciences
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.